The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor
Open accessAbstract
BACKGROUND: Ivacaftor improves outcomes in cystic fibrosis (CF) patients with the G551D mutation; however, effects on respiratory microbiology are largely unknown. This study examines changes in CF respiratory pathogens with ivacaftor and correlates them with baseline characteristics and clinical response. METHODS: The G551D Observational Study enrolled a longitudinal observational cohort of US patients with CF aged 6 years and older with at least 1 copy of the G551D mutation. Results were linked with retrospective and prospective culture data in the US Cystic Fibrosis Foundation's National Patient Registry. Pseudomonas aeruginosa infection category in the year before and year after ivacaftor was compared and correlated with clinical findings. RESULTS: Among 151 participants prescribed ivacaftor, 29% (26/89) who were culture positive for P. aeruginosa the year prior to ivacaftor use were culture negative the year following treatment; 88% (52/59) of those P. aeruginosa free remained uninfected. The odds of P. aeruginosa positivity in the year after ivacaftor compared with the year prior were reduced by 35% (odds ratio [OR], 0.65; P < .001). Ivacaftor was also associated with reduced odds of mucoid P. aeruginosa (OR, 0.77; P = .013) and Aspergillus (OR, 0.47; P = .039), but not Staphylococcus aureus or other common CF pathogens. Patients with intermittent culture positivity and higher forced expiratory volume in 1 second (FEV1) were most likely to turn culture negative. Reduction in P. aeruginosa was not associated with change in FEV1, body mass index, or hospitalizations. CONCLUSIONS: Pseudomonas aeruginosa culture positivity was significantly reduced following ivacaftor treatment. Efficacious CFTR modulation may contribute to lower frequency of culture positivity for P. aeruginosa and other respiratory pathogens, particularly in patients with less established disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Self-citation
Cited by
Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity
Flume, P. A., Chalmers, J. D., & Olivier, K. N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31767-7 · Cited by 545
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Lopes-Pacheco, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01662 · Cited by 535
Nichols, D. P., Paynter, A. C., Heltshe, S. L., Donaldson, S. H., Frederick, C. A., Freedman, S. D., Gelfond, D., Hoffman, L. R., Kelly, A., Narkewicz, M. R., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202108-1986oc · Cited by 398
Self-citationHisert, K. B., Heltshe, S. L., Pope, C., Jorth, P., Wu, X., Edwards, R. M., Radey, M., Accurso, F. J., Wolter, D. J., Cooke, G., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1954oc · Cited by 389
Self-citationVeit, G., Roldan, A., Hancock, M. A., Da Fonte, D. F., Xu, H., Hussein, M., Frenkiel, S., Matouk, E., Velkov, T., & Lukacs, G. L. (2020) · JCI Insight · doi:10.1172/jci.insight.139983 · Cited by 250
Bessonova, L., Volkova, N., Higgins, M., Bengtsson, L., Tian, S., Simard, C., Konstan, M. W., Sawicki, G. S., Sewall, A., Nyangoma, S., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-210394 · Cited by 214
CFTR modulator therapy: Transforming the landscape of clinical care in cystic fibrosis
Taylor-Cousar, J. L., Robinson, P. D., Shteinberg, M., & Downey, D. G. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01609-4 · Cited by 173
CFTR modulator therapies – Effect on life expectancy in people with cystic fibrosis
Balfour-Lynn, I. M., & King, J. A. (2022) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2020.05.002 · Cited by 85
Kirwan, L., Fletcher, G., Harrington, M., Jeleniewska, P., Zhou, S., Casserly, B., Gallagher, C. G., Greally, P., Gunaratnam, C., Herzig, M., et al. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201802-149oc · Cited by 58
The impact of CFTR modulator therapies on CF airway microbiology
Rogers, G. B., Taylor, S. L., Hoffman, L. R., & Burr, L. D. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.07.008 · Cited by 52
New Therapies to Correct the Cystic Fibrosis Basic Defect
Bergeron, C., & Cantin, A. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126193 · Cited by 22
Cystic fibrosis – Ten promising therapeutic approaches in the current era of care
Somayaji, R., Nichols, D. P., & Bell, S. C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1805733 · Cited by 12
Metadata
- Authors
- Heltshe, S. L., Mayer-Hamblett, N., Burns, J. L., Khan, U., Baines, A., Ramsey, B. W., & Rowe, S. M.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-11-25
- Volume
- 60
- Issue
- 5
- Pages
- 703-712
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2101012696
- Cited by
- 239
- References
- 1
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.